FORM
6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Private Issuer
Pursuant
to Rule 13a - 16 under
the
Securities Exchange Act of 1934
ICON
2008
Guidance
ICON
plc
(Registrant’s
name)
0-29714
(Commission
file number)
South
County Business Park, Leopardstown, Dublin 18, Ireland.
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Yes___X___ No_______
Indicate
by check mark whether the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes______ No___X___
Indicate
by check mark whether the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes______ No___X___
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes_______ No___X___
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):82N/A
November
26th,
2007
ICON
plc announce date for Financial Guidance 2008
Dublin,
Ireland, November 22nd 2007 – ICON plc (NASDAQ: ICLR), today announced that it
will release its fiscal year 2008 financial guidance on Wednesday 19th December,
before
the market opens. The release will be available on the ICON Web
site at www.iconplc.com .
At
9:00
a.m. EST 14:00 GMT the company will host a conference call followed by a Q&A
session. The call can be heard on live on the internet via
www.iconplc.com .
Enquiries:
Investor
Relations 1-888-381-7923 or
Ciaran
Murray CFO + 353 –1-291-2000
Both
at
ICON.
ICON
plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The Company
specializes in the strategic development, management and analysis of programs
that support clinical development - from compound selection to Phase I-IV
clinical studies. ICON teams have successfully conducted over 1,900 development
projects and over 2,300 consultancy engagements across all major therapeutic
areas. ICON currently has approximately 5,500 employees, operating from 66
locations in 34 countries. Further information is available at
www.iconplc.com.
The
statements made in this Press Release may contain forward-looking statements
that involve a number of risks and uncertainties. In addition to the
matters described in this Press Release, the ability to maintain large client
contracts or enter into new contracts, maintain client relationships and the
ability to manage the opening of new offices, the integration of new business
mergers and acquisitions, as well as other risks and uncertainties detailed
from
time to time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8
and
F-3, may affect the actual results achieved by ICON. ICON disclaims
any intent or obligation to update these forward-looking
statements.
Source:
ICON plc
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| ICON plc | ||
| Date: November 26, 2007 | /s/ Ciaran Murray | |
| Ciaran Murray | ||
| Chief Financial Officer |